



1 fu

Docket No. CEN 5017USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : NAKADA ET AL

Serial No. : 10/808,699

Art Unit: 5898

Filed : MARCH 25, 2004

Examiner: HADDAD, MAHER M

For : USE OF EMMPRIN ANTAGONISTS FOR THE TREATMENT OF
DISEASES ASSOCIATED WITH EXCESSIVE ANGIOGENESIS

I hereby certify that this correspondence is being deposited with the
United States Postal Service as first class mail in an envelope addressed
to: Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

JUNE 23, 2006

(Date of Deposit)

KENNETH J. DOW

(Name of applicant, assignee, or Registered Representative)

/ Kenneth J. Dow /

(Signature)

June 23, 2006

(Date of Signature)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this

information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

☒ In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required.

☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐ the first or ☐ second After Final Submission, therefore:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/CEN5017USNP/KD the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

- ☐ Statement in Accordance with §1.97(e) (attached); or
- ☐ Please charge Deposit Account No. 10-0750/CEN5017USNP/KD the fee of \$180.00 as set forth in §1.17(p).

☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with §1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p).

☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.

☐ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:

☐ In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

☐ Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a) (2).

☐ There are no listed references which are not in the English language.

☐ The relevance of those listed references which are not in the English language is as follows:

☐ Attached are copies of search report(s) from corresponding patent application(s), which are listed on the attached Submission Under MPEP 609 D.


☐ Attached are the following non-published pending patent applications which may be deemed relevant, which are listed on the attached Submission Under MPEP 609 D.

Please charge any deficiency or credit any overpayment to Deposit Account No. 10-0750/CEN5017USNP/KD. This form is submitted in triplicate.

Respectfully submitted,

/ Kenneth J. Dow /
Kenneth J. Dow
Reg. No. 32,890
Attorney for Applicants

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, NJ 08933-7003
(610) 651-7422
DATED: JUNE 23, 2006



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 3

<i>Application Number</i>	10/808,699
<i>Filing Date</i>	MARCH 25, 2004
<i>First Named Inventor</i>	NAKADA
<i>Group Art Unit</i>	5898
<i>Examiner Name</i>	HADDAD, MAHER M
<i>Attorney Docket Number</i>	CEN 5017USNP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

<i>Application Number</i>	10/808,699
<i>Filing Date</i>	MARCH 24, 2004
<i>First Named Inventor</i>	NAKADA
<i>Group Art Unit</i>	5898
<i>Examiner Name</i>	HADDAD, MAHER M
<i>Attorney Docket Number</i>	CEN 5017USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		BIWAS ETA L, "The Human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily." CANCER RES., 1995, pp 434-439, Vol. 55.	
		COUSSENS ET AL, "Matrix metalloproteinase inhibitors and cancer: trials and tribulations." SCIENCE, 2002, pp 2387-2392, VOL. 295.	
		DERYUGINA ET AL, "Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis." CANCER RES., 2002, pp 580-588, Vol. 62.	
		ELLIS ET AL, "Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor." CANCER RES., 1989, pp 3385-3391, VOL. 49.	
		FOLKMAN ET AL, "Angiogenesis in cancer, vascular, rheumatoid and other disease," NAT MED, 1995, pp 27-31, Vol. 1.	
		GUO ET AL, "Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells." J. BIOL CHEM, 1997, pp 24-27, VOL. 272.	
		HESLOP ET AL, "Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1." Lancet, 1995, pp 805-806, VOL. 346.	
		JAVADPOUR ET AL, "Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer - an update," EUR UROL, 1992, pp Suppl 1:1-4, Vol. 21.	
		KATAOKA ET AL, "Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase." CANCER RES, 1993, pp 3154-3158, Vol. 53.	
		KLAGSBRUN ET AL, "Molecular angiogenesis," CHEM BIOL, 1999, R217-24, Vol. 6.	
		KOCH ET AL, "T cell activation-associated epitopes of C147 in regulation of the T cell response and their definition by antibody affinity and antigen density." INTERNAT. IMMUNOL., 1999, pp 777-786, Vol. 11.	
		MURAOKA ET AL, "Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers," INT J CANCER, 1993, pp 19-26, Vol. 55.	
		POLETTE ET AL, "Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers," J HISTOCHEM CYTOCHEM, 1997, pp 703-709, Vol. 45.	
		SAMESHIMA ET AL, "Expression of EMMPRIN (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas," INT J CANCER, 2000a, pp 21-27, Vol. 88.	
		SAMESHIMA ET AL, "Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts." CANCER LETT, 2000b, pp 177-184, Vol. 157.	
		SOUNNI ET AL, "MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression," FASEB J, 2002, pp 5550-5564, Vol. 16.	
		STAFFLER ET AL, "Selective inhibition of T cell activation via CD 147 through novel	

		modulation of lipid rafts," J. IMMUNOL., 2003, pp 1707-1714, Vol. 171.	
		TANG ET AL, "Tumor-stroma interaction: Positive feedback of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN," MOL. CANCER RES., 2004, pp 73-80, VOL. 2.	
		ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metalloproteinase inducer," AM J PATHOL., 2001, pp 1921-1928, Vol. 158.	
		US2003/0027161 (Bejanin et al) 6 FEBRUARY 2003 (06.02.2003), see paragraph 1133.	
		ZUCKER S. "Tumor cell-stromal cell interactions in cancer. Grant application from the Department of Veterans Affairs. 24 August 2000 (24.08.2000)	
		LOOKSMART, EMMPRIN: Its role in tumor angiogenesis and metastasis. 2001, page 1.	
		ZUCKER ET AL. "Extracellular matrix metalloproteinase inducer (EMMPRIN) facilitates tumor angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting. (March 1998), Vol. 39, pp 41.	
		SAMESHIMA et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 1 September 2000 (01.09.2000) Vol. 157, No. 2, pp 177-184.	
		ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol. 2001, Vol. 158, No. 6, pp 1921-1928.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

[illegible][illegible][illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--